Novartis
Novartis is a Basel, Switzerland-headquartered global innovative-medicines (pharmaceutical) company formed in 1996 from the merger of Ciba-Geigy and Sandoz; following the 2023 Sandoz spin-off it operates as a single Innovative Medicines segment focused on oncology, immunology, neuroscience, cardiovascular/renal/metabolic and established medicines. It reported roughly $51.7B revenue for FY2024 (TTM ~$56.7B end-2025) and employs on the order of 76,000-105,000 people across ~130 locations, with medicines reaching nearly 300 million people. For AGD, the relevant signal is not its drug portfolio but its high-complexity, contact-sensitive manufacturing footprint: pioneering CAR-T cell therapy (Kymriah), market-leading radioligand therapies (Pluvicto, Lutathera), and aseptic fill-finish / injectable device production — all regulated, low-tolerance, and today heavily manual.
Recommended pilots
Best wedge: both primitives at works_in_demos, but aseptic sterile-connection and sub-mm sterility are real blockers; demo-level not pilot-proven.
Soft-body handling is solid but rigid_insertion is early; tight tolerance plus aseptic line constraints keep it a stretch.
All use cases — ranked
● validated · ○ researched| Use case | Source | Failure tol. | Tactile | Readiness | Demand |
|---|---|---|---|---|---|
| ★Sterile connection and manipulation of flexible bags/tubing in CAR-T cell processing ↗ | low | high | stretch | promising | |
| ★De-nest and present filled glass vials/syringes for aseptic inspection ↗ | low | high | stretch | promising | |
| Insert prefilled glass syringe into autoinjector and seat snap-fit closures ↗ | medium | very high | aspirational | promising | |
| Handle, dispense and seal radioligand-therapy vials within shielded isolators/hot cells ↗ | low | high | aspirational | strong |